A Multicenter, Randomized, Open-label Phase 3 Study Comparing the Efficacy and Safety of IBI362 Versus Semaglutide in Chinese Participants With Early Type 2 Diabetes and Obesity (DREAMS-3)

This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects. Subjects will be randomly assigned to IBI362 6 mg and Semalgutide 1 mg groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 40-week double-blind treatment period, and a 4-week drug withdrawal safety follow-up period

Start Date29 Feb 2024

Sponsor / Collaborator

Innovent Biologics (Suzhou) Co. Ltd.

CTR20234187 / RecruitingPhase 3

一项在经单纯饮食运动干预伴/不伴二甲双胍单药治疗血糖、体重控制不佳的中国早期2 型糖尿病合并肥胖受试者中评估IBI362 和司美格鲁肽的疗效和安全性的多中心、随机、开放标签临床研究

[Translation] A multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of IBI362 and semaglutide in Chinese obese subjects with early type 2 diabetes who have poor blood sugar and weight control after simple diet and exercise intervention with or without metformin monotherapy

验证IBI362第40周的降糖和减重的复合疗效优于司美格鲁肽

[Translation]

Verify that the combined efficacy of IBI362 in reducing blood sugar and weight at week 40 is superior to that of semaglutide

Start Date26 Feb 2024

Sponsor / Collaborator

Innovent Biologics (Suzhou) Co. Ltd.

[+2]

NCT06164873 / RecruitingPhase 3

A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2)

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Start Date27 Dec 2023

Sponsor / Collaborator

Innovent Biologics (Suzhou) Co. Ltd.

100 Clinical Results associated with Mazdutide

100 Translational Medicine associated with Mazdutide

100 Patents (Medical) associated with Mazdutide

Literatures (Medical) associated with Mazdutide

01 Jan 2024·Diabetes care

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Article

Author: Wang, Xiaoyun ; Cheng, Zhifeng ; Jin, Ping ; Qian, Lei ; Ye, Shandong ; Yang, Wenying ; Gu, Xuejiang ; Zhang, Xin ; Gan, Shenglian ; Ma, Jianhua ; Deng, Huan ; Wang, Guixia ; Shi, Bimin ; Sun, Juan ; Li, Haoyu ; Ma, Guoqing ; Li, Li ; Ma, Qingyang ; Liu, Dexue ; Ji, Linong ; An, Pei ; Zhang, Bo ; Yu, Ting ; Jiang, Hongwei ; Chen, Ji ; Yi, Jianjun

OBJECTIVE:

We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, a once-weekly glucagon-like peptide 1 and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS:

Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0–10.5% [53–91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dulaglutide (n = 50), or placebo (n = 51) subcutaneously for 20 weeks. The primary outcome was change in HbA1c from baseline to week 20.

RESULTS:

Mean changes in HbA1c from baseline to week 20 ranged from −1.41% to −1.67% with mazdutide (−1.35% with dulaglutide and 0.03% with placebo; all P < 0.0001 vs. placebo). Mean percent changes in body weight from baseline to week 20 were dose dependent and up to −7.1% with mazdutide (−2.7% with dulaglutide and −1.4% with placebo). At week 20, participants receiving mazdutide were more likely to achieve HbA1c targets of <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) and body weight loss from baseline of ≥5% and ≥10% compared with placebo-treated participants. The most common adverse events with mazdutide included diarrhea (36%), decreased appetite (29%), nausea (23%), vomiting (14%), and hypoglycemia (10% [8% with placebo]).

CONCLUSIONS:

In Chinese patients with type 2 diabetes, mazdutide dosed up to 6 mg was generally safe and demonstrated clinically meaningful HbA1c and body weight reductions.

01 Dec 2022·EClinicalMedicine

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

Article

Author: Deng, Huan ; Wen, Jie ; Jiang, Hongwei ; Gao, Leili ; Feng, Liqi ; Yu, Lei ; Song, Baili ; Ma, Qingyang ; Ji, Linong ; Cai, Chenghang ; Qian, Lei ; Yang, Jing

Background:

Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week body weight loss up to 6.4% at doses up to 6 mg in Chinese adults with overweight or obesity. We further explored the safety and efficacy of mazdutide dosed up to 9 mg and 10 mg.

Methods:

In this randomised, placebo-controlled, multiple-ascending-dose phase 1b trial, we enrolled adults (aged 18-75 years, both inclusive) with overweight (body-mass index [BMI] ≥24 kg/m²) accompanied by hyperphagia and/or at least one obesity-related comorbidity or obesity (BMI ≥28 kg/m²) from five hospitals in China. Eligible participants were randomly assigned (2:1) within each cohort by using an interactive web-response system to receive once-weekly subcutaneous mazdutide or placebo for 12 weeks in the 9 mg cohort (3 mg weeks 1-4; 6 mg weeks 5-8; 9 mg weeks 9-12) and for 16 weeks in the 10 mg cohort (2.5 mg weeks 1-4; 5 mg weeks 5-8; 7.5 mg weeks 9-12; 10 mg weeks 13-16). The participants, investigators, study site personnel involved in treating and assessing participants in each cohort and sponsor personnel were masked to treatment allocation. The primary outcomes were safety and tolerability of mazdutide, assessed from baseline to end of follow-up in all participants who received at least one dose of the study treatment. The secondary outcomes included the change from baseline to week 12 or week 16 in body weight, waist circumference and BMI. This trial is registered with ClinicalTrials.gov, NCT04440345.

Findings:

Between Mar. 1, 2021 and Mar. 26, 2021, a total of 24 participants were enrolled, with eight randomly assigned to mazdutide and four to placebo in each cohort. One participant receiving mazdutide and two receiving placebo in the 10 mg cohort withdrew consent and quitted the study. No serious adverse event was reported. All treatment-emergent adverse events (TEAEs) were mild or moderate in severity and most commonly-reported TEAEs were upper respiratory tract infection, diarrhoea, decreased appetite, nausea, urinary tract infection, abdominal distension and vomiting. The mean percent change from baseline to week 12 in body weight were -11.7% (SE 1.5) for participants receiving mazdutide in the 9 mg cohort and -1.8% (1.6) for participants receiving placebo (estimated treatment difference [ETD]: -9.8%; 95% confidence interval [CI]: -14.4, -5.3; P = 0.0002). The mean percent change from baseline to week 16 in body weight were -9.5% (SE 1.7) for participants receiving mazdutide in the 10 mg cohort and -3.3% (1.9) for participants receiving placebo (ETD: -6.2%; 95% CI: -11.5, -0.9; P = 0.024). In addition, compared with placebo, mazdutide achieved more profound reductions in waist circumference and BMI.

Interpretation:

Mazdutide dosed up to 9 mg and 10 mg was both well tolerated and showed a favourable safety profile. High-dose mazdutide showed promising 12-week body weight loss, holding great potential for the treatment of moderate-to-severe obesity. A larger and longer phase 2 trial will further evaluate the efficacy and safety of high-dose mazdutide in Chinese adults with obesity.

Funding:

Innovent Biologics, Inc.

01 Sep 2021·EClinicalMedicine

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study

Article

Author: Qian, Lei ; Han-Zhang, Han ; Song, Baili ; Jiang, Hongwei ; Feng, Liqi ; An, Pei ; Deng, Huan ; Ma, Qingyang ; Li, Li ; Liu, Meng ; Ji, Linong

BACKGROUND:

IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes. The aim of this randomised, placebo-controlled, multiple ascending dose phase 1b study was to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI362 in Chinese adults with overweight or obesity.

METHODS:

This study enrolled adults with overweight (body mass index [BMI]≥24 kg/m²) accompanied by hyperphagia and/or at least one comorbidity or obesity (BMI≥28 kg/m²) from six study centres in China. Eligible participants were randomised 2:1 to receive once-weekly subcutaneous injection of IBI362 or placebo in each of the three ascending dose cohorts for 12 weeks with additional 8 weeks of safety follow-up. The dose-escalation regimens were: 3.0 mg cohort (1.0 mg weeks 1-4; 2.0 mg weeks 5-8; 3.0 mg weeks 9-12); 4.5 mg cohort (1.5 mg weeks 1-4; 3.0 mg weeks 5-8; 4.5 mg weeks 9-12); 6.0 mg cohort (2.0 mg weeks 1-4; 4.0 mg weeks 5-8; 6.0 mg weeks 9-12). The participants, investigators and study site personnel involved in treating and assessing participants within each cohort were masked to treatment allocation. The primary endpoints were safety and tolerability of IBI362. This study is registered with ClinicalTrials.gov, number NCT04440345.

FINDINGS:

Between June 15^th, 2020 and January 15^th, 2021, 12 participants were enrolled and randomised in each cohort. Throughout the study, no participant discontinued the treatment due to safety reason and no serious adverse event was reported. Gastrointestinal adverse events and decreased appetite were the most common adverse events and mostly mild in severity. Three participants receiving IBI362 reported mild and asymptomatic cardiac disorders revealed by electrocardiogram. Estimated percent changes in mean body weight from baseline to week 12 were -4.81% (95%CI -6.61 to -3.02), -6.40% (-8.23 to -4.58) and -6.05% (-7.91 to -4.18) for participants receiving IBI362 in the 3.0 mg, 4.5 mg and 6.0 mg cohort, respectively, compared with 0.60% (-0.86 to 2.07) for those receiving placebo.

INTERPRETATION:

IBI362 was well tolerated and showed a body weight-lowering effect in Chinese adults with overweight or obesity.

FUNDING:

Innovent Biologics.

News (Medical) associated with Mazdutide

12 Jun 2024

·www.prnewswire.com

Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA) 84th Scientific Sessions in Orlando from June 21 -24. Innovent will share the results from the first phase 3 study of mazdutide in Chinese adults with obesity and overweight (GLORY-1), an exploratory analysis of GLORY-1 on liver steatosis, as well as a Phase 2 study of mazdutide 9 mg in adults with obesity during one oral presentation and two posters. Details are listed below: Title: Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1) Abstract #: 1856-LB Presentation Form: Oral（ePoster Theater） Time: 2024 June 23, 13: 30 PM – 13: 40 PM（EST） Presenter: Dr. Linong Ji, Peking University People's Hospital Title: Improvement of Liver Steatosis by Mazdutide in Chinese Participants with Overweight or Obesity—An Exploratory Analysis of GLORY-1 Abstract # : 1857-LB Presentation Form : Poster presentation Title: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg/m2 or more Abstract # : 1866-LB Presentation Form ：Poster presentation Dr. Lei Qian, Vice President of Clinical Development of Innovent, stated, " We are excited to announce the results of GLORY-1 at ADA scientific sessions. Mazdutide is the first GLP-1R/GCGR dual agonist that succeeded in a Phase 3 registration study for people with overweight/obesity. Meanwhile, the strong results of a Phase 2 study of mazdutide 9mg in Chinese adults with moderate-to-severe obesity will also be released at ADA, and the corresponding Phase 3 GLORY-2 is currently ongoing. Mazdutide is anticipated to provide an individualized, effective and safe weight management option for people with overweight or obesity at different severities. " About Mazdutide (IBI362) Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, with the effects of GLP-1 receptor agonists to promote insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated robust weight loss and glucose-lowering effects in clinical studies as well as improvements in multiple cardio-metabolic indicators including reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, liver fat content and improved insulin sensitivity. Currently, five Phase 3 studies of mazdutide in Chinese adults with overweight or obesity (GLORY-1 and GLORY-2) and type 2 diabetic (DREAMS-1, DREAMS-2 and DREAMS-3) subjects are underway, where GLORY-1 and DREAMS-2 studies have met their primary endpoints. In February 2024, the first NDA of mazdutide was accepted by the CDE of the NMPA of China for chronic weight management in adults with obesity or overweight. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 4 new drug applications under the NMPA review, 4 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or is otherwise inaccurate. SOURCE Innovent Biologics

Phase 2License out/inPhase 3NDA

28 May 2024

·www.fiercebiotech.com

Innovent to take IL-23 psoriasis drug to Chinese regulators after phase 3 win

The “strong efficacy” was maintained through Week 52 in both of the picankibart cohorts, Innovent said. Innovent’s psoriasis contender to IL-23 drugs like Tremfya and Skyrizi cleared skin and improved the severity of disease in a phase 3 test, setting up the company to seek approval from Chinese regulators. The anti-IL-23 monoclonal antibody, called picankibart, hit all primary and key secondary endpoints in the late-stage CLEAR-1 trial of 500 Chinese patients with moderate to severe plaque psoriasis. Specifically, 80.3% of patients who received picankibart achieved a 90% or greater improvement in their Psoriasis Area and Severity Index (PASI) score at 16 weeks compared to just 2% of participants who received placebo. A physician’s assessment at the same point—the other primary endpoint of the trial—produced similar results, with 93.5% of patients achieving clear or almost-clear skin compared to 13.1% of the placebo cohort. Patients who received picankibart started with a 200-mg injection and then received the same dose again at weeks 4 and 8 before being split into those who received either a 100-mg or 200-mg dose every 12 weeks. The “strong efficacy” was maintained through Week 52 in both of the picankibart cohorts, said Innovent, although yearlong data were only shared for the 200-mg group. Of these patients, 84.9% still had a PASI score of 90% or above at this point, while 85.9% maintained their clear or almost-clear skin. “These results underpin the long-term robust efficacy of picankibart in treating moderate to severe psoriasis,” the biotech said in the May 27 release. Picankibart is designed to be given less frequently than some rivals. While the FDA has already approved antibodies in the U.S. against the IL23p19 subunit—with Sun Pharma’s Ilumya joining Johnson & Johnson’s Tremfya and AbbVie’s Skyrizi among the authorized products—Innovent sees value in developing an extended half-life treatment that can be dosed less frequently. “Achievement of all primary and key secondary endpoints in CLEAR-1 has supported picankibart's outstanding efficacy and favorable safety as a new generation of IL-23p19 target drugs,” said Lei Qian, M.D., Ph.D., vice president of clinical development at Innovent. Innovent will use yesterday’s results to prepare an application to Chinese regulators to approve picankibart as a “more convenient, friendly and effective treatment regimen for patients with moderate to severe plaque psoriasis,” Qian said. J&J has another IL-23 psoriasis option in the works courtesy of an IL-23R antagonist peptide called JNJ-2113. The Protagonist Therapeutics-partnered candidate fell short of the high bar set by injectable treatments in a phase 2 trial last year, but the convenience of oral delivery means the companies have still pushed the asset into phase 3. The picankibart results mark the latest in a string of clinical wins for Innovent this year. A thyroid eye disease rival to Amgen’s Tepezza hit its phase 3 endpoints, while the GLP-1R/GCGR dual agonist mazdutide licensed from Eli Lilly has demonstrated success in both diabetes and weight loss.

Clinical ResultPhase 3Phase 2

09 May 2024

·www.fiercebiotech.com

Lilly's next-gen obesity drug brings Innovent a phase 3 win in diabetes

Patients in both the mazdutide cohorts showed improved glycated hemoglobin (HbA1c) levels when compared to those on Trulicity. Innovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli Lilly's diabetes and heart drug Trulicity when it came to glycemic control in patients with Type 2 diabetes. China-based Innovent secured the rights to mazdutide from Lilly back in 2019 for an undisclosed sum. Innovent kicked off this year showing success in a weight loss study that the company declared as demonstrating the drug is “the first GLP-1R/GCGR dual agonist succeeding in phase 3 trials.” That success seems to have continued into the DREAMS-2 trial, which enrolled 731 patients in China with Type 2 diabetes, who received either 4-mg or 6-mg doses of mazdutide or 1.5 mg of Lilly’s own approved diabetes drug Trulicity. After 28 weeks of treatment, patients in both the mazdutide cohorts showed improved glycated hemoglobin (HbA1c) levels when compared to those on Trulicity, hitting the trial’s primary endpoint. The key secondary endpoints also showed mazdutide's superior benefits in terms of the proportion of patients who saw weight loss of more than 5% and those whose HbA1c levels was less than 7%, Innovent explained in the May 8 postmarket release. While gastrointestinal reactions were the most common adverse events, most of these cases were mild to moderate in severity, mainly occurring during the first 12-week titration period, the biotech explained. Data from DREAMS-2 will go toward the ongoing review of mazdutide by Chinese regulators for weight management, Innovent said. A similar study, DREAMS-1, is due to read out in mid-2024, after which the company will also apply to the regulator for mazdutide’s approval as a diabetes treatment. “In the DREAMS-2 study, mazdutide showed comprehensive superiority to dulaglutide, one of the most-described glucose-lowering drugs in the world,” Lei Qian, M.D., Ph.D., vice president of clinical development of Innovent, said in the release. “We will further analyze the study data, and strive to submit an NDA for T2D as soon as possible this year, so as to help more Chinese T2D patients to achieve target blood glucose levels and acquire metabolic benefits,” he added. “At the same time, we look forward to the performance of mazdutide in the DREAMS-3 study, a head-to-head study with semaglutide." Lilly has the rights to develop mazdutide outside of China and continues to list the candidate in its phase 2 pipeline as a treatment for obesity.

Clinical ResultPhase 3Phase 2

100 Deals associated with Mazdutide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	NDA/BLA	CN	Innovent Biologics (Suzhou) Co. Ltd.	07 Feb 2024
Early-onset type II diabetes	Phase 3	CN	Innovent Biologics (Suzhou) Co. Ltd.	29 Feb 2024
Diabetes Mellitus, Type 2	Phase 3	CN	Innovent Biologics (HK) Ltd.	20 Nov 2022
Renal Insufficiency	Phase 1	CN	Innovent Biologics (HK) Ltd.	05 May 2023
Nonalcoholic Steatohepatitis	IND Approval	CN	Innovent Biologics (Suzhou) Co. Ltd.	22 Mar 2023
Hyperuricemia	Preclinical	CN	Innovent Biologics (Suzhou) Co. Ltd.	12 Jul 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05607680 (GLORY-1, ADA2024) Manual	Phase 3	Overweight \| Obesity	610	mazdutide 4 mg	aeukxijdfy(lnbdaxmqjp) = hmlhdbutze jcyskhdchr (grgqhpcyhd, 0.538) Met View more	Positive	14 Jun 2024
				mazdutide 6 mg	aeukxijdfy(lnbdaxmqjp) = kubikodejw jcyskhdchr (grgqhpcyhd, 0.558) Met View more
NCT05606913 (DREAMS-2, Corporate Publications) Manual	Phase 3	Diabetes Mellitus, Type 2	731	mazdutide 4.0 mg	tvpedputiv(itnberodvv) = the superiority test was further performed, and both mazdutide 4.0 mg and 6.0 mg achieved superiority to dulaglutide 1.5 mg. rpyckqiwaz (vimbmzbwwy ) Met View more	Superior	09 May 2024
				mazdutide 6.0 mg
NCT05607680 (GLORY-1, Corporate Publications) Manual	Phase 3	Overweight \| Obesity	610	玛仕度肽 4 mg	yfepurczys(mtplsoizbt) = 主要研究终点顺利达成：玛仕度肽 4 mg和6 mg组受试者治疗32周后体重相对基线的百分比变化显著优于安慰剂组 mvltrghuii (ljzsuegalt ) Met View more	Positive	09 Jan 2024
				玛仕度肽 6 mg
NCT04904913 (Literature) Manual	Phase 2	Overweight \| Obesity	248	mazdutide 3 mg	wsptxumoob(abjuwdptuv) = atdlhtgbmm skfegmmvwd (sqjmptnibb, 0.7) View more	Positive	14 Dec 2023
				mazdutide 4.5 mg	wsptxumoob(abjuwdptuv) = zsmuihirle skfegmmvwd (sqjmptnibb, 0.7) View more
NCT04965506 (Literature) Manual	Phase 2	Diabetes Mellitus, Type 2	250	Mazdutide 3 mg	agvaayomfl(nytdicinsh) = oppqatqkef rwgrciyfwd (ccjfkdcpxd ) View more	Positive	09 Nov 2023
				Mazdutide 4.5 mg	agvaayomfl(nytdicinsh) = lzacagitqm rwgrciyfwd (ccjfkdcpxd ) View more
NCT04904913 (PRNewswire) Manual	Phase 2	Obesity	80	Mazdutide 9 mg	ytvyxvybuo(dkwijoblbe): Difference(%) = -15.4 Met View more	Positive	30 Oct 2023
				placebo
NCT04904913 (Corporate Publications) Manual	Phase 2	Obesity	80	IBI362 9 mg	qgoaeyiqhz(pzlqwlljvr): difference = -15.4% (95% CI, -18.8 to -11.9), P-Value = <0.0001 Met View more	Positive	11 May 2023
				placebo
NCT03928379 \| NCT03325387 (ADA2022)	Not Applicable	Diabetes Mellitus, Type 2	-	LY3305677	tzaukryqcx(mpogqtvtut) = The most common treatment-emergent adverse events in both studies (decreased appetite, nausea, and diarrhea) were mostly mild in severity aryqhdfhhg (wvvprohhda ) View more	-	01 Jun 2022
ADA2021	Not Applicable	-	48	LY3305677	fezzuxbvox(ucpuwumyek) = exndjwlwfc dbjqviyxqf (baduhervry ) View more	-	01 Jun 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Mazdutide

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation